KT 5720
Effect of pharmacological inhibitors on EAAT2-Prom activity, and mRNA and protein expression in PHFA after various treatment protocols. (A–C) EAAT2-Prom activity in PHFA either untreated (−) or treated with EGF (30 ng/ml) (A), bromo-cAMP (250 μM) (B), or TNF-α (200 units/ml) (C) in the absence (−) or presence (+) of KT5720 (5 μM), AG1478 (1 μM), PDTC (100 μM), wortmanin (WRT) (100 nM), or PD98049 (PD) (50 μM). The duration of the assay was 4 days. (D) Effect of the various treatment protocols on EAAT2 and GAPDH mRNA levels. (Upper) Relative EAAT2 RNA expression versus GAPDH expression compared with control untreated or treated samples based on scanning of autoradiograms. (Lower) Actual Northern blots. (E) Effect of the various treatment protocols on EAAT2 and ACTIN protein levels. (Upper) Relative EAAT2 protein expression versus ACTIN expression compared with control untreated or treated samples based on scanning of autoradiograms. Individual experiments were performed three times with triplicate samples, and SD from the mean is presented. |
Catalog No. | ES1177 |
---|---|
CAS Number | 108068-98-0 |
Formula | C32H31N3O5 |
M. Wt | 537.61 |
Purity | >98 % |
Solubility | Soluble to 50 mM in DMSO |
Chemical Name | (9R,10S,12S)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, hexyl ester |
Synonyms | N/A |
Storage | Desiccate at -20°C |
Please complete the form below and we will contact you shortly.
Another custom CMS block displayed as a tab. You can use it to display info about returns and refunds, latest promotions etc. You can put your own content here: text, HTML, images - whatever you like. There are many similar blocks accross the store. All CMS blocks are editable from the admin panel.
Lorem ipsum dolor sit, consectetur adipiscing elit. Etiam neque velit, blandit sed scelerisque quis. Nullam ornare enim nec justo bibendum lobortis. In eget metus.